Dashboard
Low Debt Company with Strong Long Term Fundamental Strength
- Healthy long term growth as Net Sales has grown by an annual rate of 15.02% and Operating profit at 17.74%
- Company has a low Debt to Equity ratio (avg) at 0.10 times
- The company has been able to generate a Return on Equity (avg) of 17.09% signifying high profitability per unit of shareholders funds
The company has declared negative results for the last 2 consecutive quarters
Stock is technically in a Bullish range
With ROCE of 16.9, it has a Fair valuation with a 3.5 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
INR 119,930 Cr (Mid Cap)
26.00
40
0.08%
0.31
16.52%
4.30
Total Returns (Price + Dividend) 
Latest dividend: 1 per share ex-dividend date: Jul-24-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Zydus Lifesciences Ltd is Rated Hold by MarketsMOJO
Zydus Lifesciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 Oct 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Zydus Lifesciences Sees Significant Open Interest Surge Amid Mixed Market Signals
Zydus Lifesciences Ltd has witnessed a notable 10.65% increase in open interest in its derivatives segment, signalling heightened market activity despite a marginal decline in its share price. This surge in open interest, coupled with volume and positioning data, offers valuable insights into investor sentiment and potential directional bets in the pharmaceutical mid-cap stock.
Read More
Zydus Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness
Zydus Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating, signalling improved price appeal for investors. This change comes amid a backdrop of mixed valuations across the Pharmaceuticals & Biotechnology sector, with Zydus now standing out for its relative affordability and solid financial metrics.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Press Release / Media Release
14-Nov-2026 | Source : BSEPress Release
Announcement under Regulation 30 (LODR)-Updates on Joint Venture
12-Nov-2026 | Source : BSECompletion of transaction
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
07-Nov-2026 | Source : BSETranscript of the post results earnings call held on November 4 2026.
Corporate Actions 
No Upcoming Board Meetings
Zydus Lifesciences Ltd has declared 100% dividend, ex-date: 24 Jul 26
Zydus Lifesciences Ltd has announced 1:5 stock split, ex-date: 06 Oct 15
Zydus Lifesciences Ltd has announced 1:2 bonus issue, ex-date: 05 Apr 10
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 41 Schemes (6.88%)
Held by 629 FIIs (7.05%)
Zydus Family Trust (pankaj R. Patel, Pritiben P. Patel And Sharvil P. Patel-trustees) (74.98%)
Life Insurance Corporation Of India (3.77%)
5.3%
Quarterly Results Snapshot (Consolidated) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 29.17% vs 16.92% in Sep 2025
YoY Growth in quarter ended Sep 2026 is -26.47% vs 38.13% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 10.94% vs 20.36% in Sep 2024
Growth in half year ended Sep 2025 is 16.91% vs 23.50% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 17.04% vs 19.27% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 12.31% vs 25.30% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 16.81% vs 18.90% in Mar 2025
YoY Growth in year ended Mar 2026 is 12.58% vs 17.26% in Mar 2025